According to the new ASCO guideline update for HER2+ BC patients, trastuzumab, pertuzumab, and a taxane are recommended for the first-line treatment, and trastuzumab deruxtecan for the second-line treatment. This evidence concerns the gene ERBB2 and breast cancer.